

SCIENTIFIC REPORTS

**OPEN**

Author Correction: Evaluation of cell penetrating peptide coated Mn:ZnS nanoparticles for paclitaxel delivery to cancer cells

N. Sanoj Rejinold¹, Yunho Han², Jisang Yoo¹, Hae Yong Seok¹, Ji Ho Park² & Yeu-Chun Kim¹

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-018-20255-x>, published online 30 January 2018

In this Article, Figure 4O is a duplication of Figure 3B. The correct Figure 4 appears below as Figure 1.

In addition, Figure 6B is a duplication of Figure 6D. The correct Figure 6 appears below as Figure 2.

¹Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. ²Department of Brain and Bioengineering, Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. Correspondence and requests for materials should be addressed to Y.-C.K. (email: dohnanyi@kaist.ac.kr)




Figure 1. *In vitro* therapeutic efficacy assessment on (A) SKOV-3 and (B) HeLa cells by PTX-CPP modified Mn:ZnS NPs after 48 h incubation; The control vehicle concentration is 50, 100, and 200 $\mu\text{g}/\text{mL}$, whereas the control PTX concentration is 10, 20 and 30 μM . The actual PTX concentration in samples are 0.2, 0.4 and 0.8 μM respectively. ($n = 6$, **represents $p < 0.01$, ***represents $p < 0.001$); (C–N) represents the apoptotic profile on SKOV-3 and HeLa cells by the developed PTX formulations with CPP modified Mn:ZnS NPs: (C) Control SKOV-3 cells; (D) Mn:ZnS NPs; (E) PEN/Mn:ZnS NPs; (F) pVEC/Mn:ZnS NPs; (G) R9/Mn:ZnS NPs and (H) Control PTX; (I) control HeLa; (J) Mn:ZnS NPs; (K) PEN/Mn:ZnS NPs; (L) pVEC/Mn:ZnS NPs; (M) R9/Mn:ZnS NPs and (N) Control PTX cells after 48 h incubation time. (O–Z) Shows the confocal laser scanning electron microscopic images on SKOV3 and HeLa cells: (O) control SKOV-3; (U) Control HeLa cells; (P, V) PTX:Mn:ZnS NPs; (Q, W) PTX:PEN/Mn:ZnS NPs; (R, X) PTX/pVEC:Mn:ZnS NPs; (S, Y) PTX:R9/Mn:ZnS NPs and (T, Z) Control PTX respectively after 48 h incubation time. Blue fluorescence is DAPI staining on the nucleus and red fluorescence indicates the Mn:ZnS NPs (scale bar = 50 μm).




Figure 2. Bio-distribution analysis of IR-780 doped samples on 4T1 tumor model. Left to right samples: Control mice, control dye, IR-780:Mn:ZnS NPs, IR-780:PEN/Mn:ZnS NPs, IR-780:pVEC/Mn:ZnS NPs, IR-780:R9/Mn:ZnS NPs respectively from 1 hour to 168 h. (B–G) shows tumor vs organ *ex vivo* bio-imaging on 4T1 tumor model one week after i.v injection. (B) Control mice; (C) control dye; (D) IR-780:Mn:ZnS NPs; (E) IR-780:PEN/Mn:ZnS NPs, (F) IR-780:pVEC/Mn:ZnS NPs, (G) IR-780:R9/Mn:ZnS NPs respectively.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018